Generating sociability to drive science: patient advocacy organizations and genetics research
- PMID: 21553639
- DOI: 10.1177/0306312710385852
Generating sociability to drive science: patient advocacy organizations and genetics research
Abstract
This paper examines how patient advocacy organizations (PAOs) representing those with rare genetic disorders drive research to their concerns. The rarity of the diseases produces a basic condition of marginalization: small numbers of widely distributed disease sufferers. The lack of promise of an eventual market makes it difficult to attract the economic and biological resources necessary for sustained research. My analysis relies mainly on 21 interviews with leaders from nine PAOs and scientists involved with them, and seeks to understand how PAOs try to attract and influence scientific research. Using a comparative framework, I find that the five main mechanisms emphasized in the literature--economic resources, social movement-style mobilization, moving early, lay expertise, and organizational controls--cannot fully explain the differences in strategies and relationships among members of my PAO sample. I propose instead to show how 'sociability'--forging close relationships with scientists and orchestrating relationships among them--enables PAOs to drive research to their concerns. I show how the strategic manipulation of sociability can give PAOs substantial influence over the research process. However, the forms of sociability that yield the greatest effects are difficult to achieve, and most forms of relationship-building offer PAOs much less influence on research.
Similar articles
-
Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.JAMA Intern Med. 2017 Mar 1;177(3):344-350. doi: 10.1001/jamainternmed.2016.8443. JAMA Intern Med. 2017. PMID: 28114624
-
The role of patient advocacy organizations in shaping genomic science.Annu Rev Genomics Hum Genet. 2013;14:579-95. doi: 10.1146/annurev-genom-091212-153525. Epub 2013 Jul 12. Annu Rev Genomics Hum Genet. 2013. PMID: 23875802 Review.
-
Collective forward-looking responsibility of patient advocacy organizations: conceptual and ethical analysis.BMC Med Ethics. 2021 Aug 23;22(1):113. doi: 10.1186/s12910-021-00680-w. BMC Med Ethics. 2021. PMID: 34425786 Free PMC article.
-
Analysis of Potential Conflicts of Interest among Otolaryngologic Patient Advocacy Organizations in 2016.Otolaryngol Head Neck Surg. 2019 Dec;161(6):967-969. doi: 10.1177/0194599819874828. Epub 2019 Sep 3. Otolaryngol Head Neck Surg. 2019. PMID: 31479391
-
Advocacy groups and their role in rare diseases research.Adv Exp Med Biol. 2010;686:515-25. doi: 10.1007/978-90-481-9485-8_28. Adv Exp Med Biol. 2010. PMID: 20824463 Review.
Cited by
-
Understanding collective agency in bioethics.Med Health Care Philos. 2016 Sep;19(3):411-22. doi: 10.1007/s11019-016-9695-4. Med Health Care Philos. 2016. PMID: 26948497
-
The social aspects of genome editing: publics as stakeholders, populations and participants in animal research.Lab Anim. 2022 Feb;56(1):88-96. doi: 10.1177/0023677221993157. Epub 2021 Feb 17. Lab Anim. 2022. PMID: 33596730 Free PMC article.
-
Involving Patient Groups in Drug Research: A Systematic Review of Reasons.Patient Prefer Adherence. 2020 Mar 12;14:587-597. doi: 10.2147/PPA.S232499. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32210544 Free PMC article.
-
Patient and interest organizations' views on personalized medicine: a qualitative study.BMC Med Ethics. 2016 May 13;17(1):28. doi: 10.1186/s12910-016-0111-7. BMC Med Ethics. 2016. PMID: 27178188 Free PMC article.
-
Human germline genome editing is illegal in Canada, but could it be desirable for some members of the rare disease community?J Community Genet. 2020 Apr;11(2):129-138. doi: 10.1007/s12687-019-00430-x. Epub 2019 Aug 16. J Community Genet. 2020. PMID: 31420817 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical